TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Science | AAAS·Feb 15

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research on t cell receptor-engineered t cell therapy is ongoing, with studies exploring its potential in treating solid tumors. The therapy's efficacy is being investigated, with some approaches focusing on enhancing t cell function and overcoming barriers to success. Various strategies, including modifications to t cells and combinations with other therapies, are being examined to improve treatment outcomes for solid tumors.

Full coverage

Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges

Frontiers·Apr 22

A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands

Nature·Jan 3

Engineered TCR-T cells secreting IFNα/anti-PD-L1 potentiate endogenous immunity to synergistically bolster the efficacy against solid tumors

ScienceDirect.com·Jun 3

Overcoming Barriers to Efficacy: Enhancing Adoptive T-Cell Therapy Success in Solid Tumors

ASCO Daily News·Dec 3

T cell receptor therapy: A new era for cell therapy in cancer treatment

AstraZeneca·Sep 19

T cell immunotherapy for solid tumors: limitations, progress, and future prospects

Frontiers·Jan 29

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength

Nature·Jan 8

Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer

PNAS·Sep 23

View original report at Science | AAAS ↗

Fetching the latest headlines…